Yahoo Finance 
Insights on the Human Growth Hormone Global Market to 2027 - by Application, Distribution Channel, Route of Administration and Region
Global Human Growth Hormone Market
Dublin, July 15, 2022 (GLOBE NEWSWIRE) -- The "Human Growth Hormone Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027" report has been added to ResearchAndMarkets.com's offering.
The global human growth hormone market reached a value of US$ 4.8 Billion in 2021. Looking forward, the publisher expects the market to reach US$ 7.9 Billion by 2027, exhibiting a CAGR of 8.66% during 2021-2027. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic. These insights are included in the report as a major market contributor.
HGH is a peptide hormone that is produced by the pituitary gland to stimulate growth in children and adults. The hormone primarily regulates growth, regeneration, repair, reproduction and metabolism of the cells, thus contributing to the overall development of the body. It also regulates body fluids, fat metabolism and bone and muscle growth. The deficiency of HGH can increase the risk of diseases and fat accumulation, whereas higher levels can cause gigantism in children and acromegaly, muscle-wasting disease and short bowel syndrome in adults.
The increasing prevalence of Turner syndrome and other growth-related disorders is one of the key factors driving the growth of the market. Turner syndrome is a chromosomal disorder that primarily affects females and is characterized by complete or partial loss of X chromosomes.
Growth hormones are often administered to reverse some of the symptoms of this disease, thereby increasing the demand for HGH drugs across the globe. Furthermore, increasing health consciousness among the masses and growing awareness regarding the preventive measures against endocrine disorders, are providing a boost to the market growth.
Various disorders, such as Prader-Willi syndrome (PWS) and idiopathic short stature (ISS), are caused by the deficiency of growth hormones in the body that can be treated using medically synthesized HGH. Other factors, including a rising utilization of HGH as performance enhancers by bodybuilders, along with the development of recombinant human growth hormone (rHGH), are projected to drive the market further.
Competitive Landscape:
The competitive landscape of the industry has also been examined with some of the key players being Eli Lilly and Company, EMD Serono Inc., F. Hoffmann-La Roche AG, Ferring B.V., Genentech Inc., Ipsen, Merck KGaA, Novartis AG, Novo Nordisk, Pfizer Inc., Sandoz, etc.
Key Questions Answered in This Report:
How has the global human growth hormone market performed so far and how will it perform in the coming years?
What has been the impact of COVID-19 on the global human growth hormone market?
What are the key regional markets?
What is the breakup of the market based on the application?
What is the breakup of the market based on the distribution channel?
What is the breakup of the market based on the route of administration?
What are the various stages in the value chain of the industry?
What are the key driving factors and challenges in the industry?
What is the structure of the global human growth hormone market and who are the key players?
What is the degree of competition in the industry?
Key Topics Covered:
1 Preface
2 Scope and Methodology
3 Executive Summary
4 Introduction
4.1 Overview
4.2 Key Industry Trends
5 Global Human Growth Hormone Market
5.1 Market Overview
5.2 Market Performance
5.3 Impact of COVID-19
5.4 Market Forecast
6 Market Breakup by Application
6.1 Growth Hormone (GH) Deficiency
6.1.1 Market Trends
6.1.2 Major Types
6.1.2.1 Adult GH Deficiency
6.1.2.2 Pediatric GH Deficiency
6.1.3 Market Forecast
6.2 Turner Syndrome
6.2.1 Market Trends
6.2.2 Market Forecast
6.3 Idiopathic Short Stature (ISS)
6.3.1 Market Trends
6.3.2 Market Forecast
6.4 Prader-Willi Syndrome (PWS)
6.4.1 Market Trends
6.4.2 Market Forecast
6.5 Small for Gestational Age
6.5.1 Market Trends
6.5.2 Market Forecast
6.6 Others
6.6.1 Market Trends
6.6.2 Market Forecast
7 Market Breakup by Distribution Channel
7.1 Hospital Pharmacy
7.1.1 Market Trends
7.1.2 Market Forecast
7.2 Retail Pharmacy
7.2.1 Market Trends
7.2.2 Market Forecast
7.3 Online Pharmacy
7.3.1 Market Trends
7.3.2 Market Forecast
7.4 Others
7.4.1 Market Trends
7.4.2 Market Forecast
8 Market Breakup by Route of Administration
8.1 Intravenous
8.1.1 Market Trends
8.1.2 Market Forecast
8.2 Intramuscular
8.2.1 Market Trends
8.2.2 Market Forecast
8.3 Subcutaneous
8.3.1 Market Trends
8.3.2 Market Forecast
8.4 Oral
8.4.1 Market Trends
8.4.2 Market Forecast
9 Market Breakup by Region
10 SWOT Analysis
11 Value Chain Analysis
12 Porters Five Forces Analysis
13 Competitive Landscape
13.1 Market Structure
13.2 Key Players
13.3 Profiles of Key Players
13.3.1 Eli Lilly and Company
13.3.1.1 Company Overview
13.3.1.2 Product Portfolio
13.3.1.3 Financials
13.3.1.4 SWOT Analysis
13.3.2 EMD Serono Inc.
13.3.2.1 Company Overview
13.3.2.2 Product Portfolio
13.3.3 F. Hoffmann-La Roche AG
13.3.3.1 Company Overview
13.3.3.2 Product Portfolio
13.3.3.3 SWOT Analysis
13.3.4 Ferring B.V.
13.3.4.1 Company Overview
13.3.4.2 Product Portfolio
13.3.4.3 Financials
13.3.5 Genentech Inc.
13.3.5.1 Company Overview
13.3.5.2 Product Portfolio
13.3.5.3 SWOT Analysis
13.3.6 Ipsen
13.3.6.1 Company Overview
13.3.6.2 Product Portfolio
13.3.6.3 Financials
13.3.7 Merck KGaA
13.3.7.1 Company Overview
13.3.7.2 Product Portfolio
13.3.7.3 Financials
13.3.8 Novartis AG
13.3.8.1 Company Overview
13.3.8.2 Product Portfolio
13.3.9 Novo Nordisk
13.3.9.1 Company Overview
13.3.9.2 Product Portfolio
13.3.10 Pfizer Inc.
13.3.10.1 Company Overview
13.3.10.2 Product Portfolio
13.3.10.3 Financials
13.3.10.4 SWOT Analysis
13.3.11 Sandoz
13.3.11.1 Company Overview
13.3.11.2 Product Portfolio
For more information about this report visit https://www.researchandmarkets.com/r/jdteh9
Attachment
CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
